with Strategic Consulting


with Strategic Consulting



European Landscape Assessment

HTA Decision Analysis

Payer research and advisory boards

Joint/Parallel Scientific Advice

Key Country Market Insights












Market Access & Value Strategy

Lifecycle Management (LCM) Strategy

Value Story & Message Development

Evidence Gap Analysis

Evidence Generation Planning (incl. RWE & PLEG)

Value-based Price Potential

Multi-national HTA strategy



Country HTA Submissions

European Launch Management

Value Communications

Questions we answer

Is it worth launching your latest asset in Europe?
US & global biotechs come to AESARA Europe for expert, evidence-based, go/no-go market access advice.
What should you invest in Europe – and when?
US & global biotechs hire AESARA Europe for asset due diligence, value-based pricing and European market access infrastructure build.
Will European payers value your medical innovation?
US & global biotechs use AESARA’s European market access industry-veterans to optimise their value evidence and product value propositions for European health technology assessments.
How should you best structure and sequence your European HTA submissions for strategic impact and operational efficiency?
US and global biotechs use AESARA's European and in-country experts to plan and execute successful HTA, pricing and reimbursement submissions
What value evidence will European HTA bodies need to see in support of your value story, target population & price?
Global biotech and pharma companies trust AESARA Europe's insight and experience to test and optimise value propositions and value evidence plans, for European HTA and reimbursement success

Strategy leaders

Gavin J. Outteridge, MA (Oxon) 

is the Managing Director of Europe for AESARA. Gavin delivers measurable business improvement for global life sciences clients through advising executives on value & access strategy, communications and organizational design.

With over 21 years of leadership experience, including 17 in life sciences, Gavin believes the life sciences sector is a social good and that a regulated market is the best way of delivering innovation and value. Consequently, he works with clients in Development and Commercialization functions to optimize how they demonstrate scientifically-sound cost-risk-benefit and, by doing so, deliver value to patients, to payers and to investors.

Prior to AESARA, Gavin was on the Executive Committee of life sciences services company Kinapse; held a change management role in Pfizer R&D; and began his working life as an officer in the Royal Air Force.

Patrizia Berto, MBA, PharmD

Patrizia Berto is AESARA’s Principal – Europe. During her 27 years in consulting, Patrizia has led multiple strategic market access, P&R and HEOR consulting projects for pipeline, launch and marketed products across a vast array of therapy areas, spanning from rare diseases to oncology, haematology and many others.

Her previous experiences include: SVP Value & Access at Regulatory Pharma Net (2020-2022), Head of Italian Office at Certara (2018-2020), Global Head of Business Development at LA-SER/Laser-Analytica (2012-2018) and Managing Director of PBE consulting (1997 – 2011). Prior to that, she spent ten years at Glaxo/GSK in market research, strategic planning, pricing and health economics.

Catherine Chamoux, PhD

has international experience acquired over thirty+ years in the pharma industry in medium-sized and large companies. She holds a PhD in Pharmacy and a Masters of Public Health from Sciences Po, Paris. She is an expert in Market Access for innovative drugs.

As a member of the leadership team of the French affiliate of a leading US biotech for 15 years, she helped establish & develop the company locally, directly negotiated product prices & access conditions, developed relationships with regulators, payors and KOLs. She also actively participated in the evidence generation and early access program strategies for our innovative therapies, including orphan drug products, highlighting the unmet needs and the products’ unique attributes.

She also has strong pan-European experience in Market Access, having most recently led the Market Access Excellence function for Europe, creating common understanding, tools, measures and co-operation between countries.

Sameera Tak, MSc

Based in the Zug, Switzerland, biotech hub, Sameera has taken on the Geschäftsführerin or operational board director role, running AESARA Europe’s newly established Swiss operations.

Sameera brings differentiated breadth of experience as well as depth of expertise to her consulting role as a peer thought partner to the industry clients.

Sameera’s market access experiences ranges from global to regional roles with expertise in payor value communication strategies, European Field Value and access communications, pricing and access strategies, portfolio and brand level competitor readiness, Tender and contracts management strategies and tactical execution.

With nearly 16 years in the biopharmaceutical industry across market access as well as R&D roles across Global and Regional levels in large and mid- sized biopharma companies gives her a well-rounded insight into strategic and tactical client needs.

Prior to AESARA, Sameera worked within the industry at Biogen International GmbH in Zug, Switzerland and Novartis AG in Basel, Switzerland and Novartis Private Limited in Hyderabad, India.

Case studies

European Sequencing Strategy
European HTA Submission Programme
European Asset Due Diligence


Change Before Change

We are forward thinking and driven by the impact you need

Biopharma DNA

We have walked in your shoes and know what needs to get done

Partner with those that have walked in your shoes

Having both the big picture perspective and the methodological know-how, our strategic consultants come from industry and have molecule-to-launch experience in a complex and changing global healthcare landscape.



Contact us

Fill out the form below, and we will be in touch shortly.